J 2017

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data

SZTURZ, Petr, Marie BUDÍKOVÁ, Jan B. VERMORKEN, Ivanka HOROVÁ, Břetislav GÁL et. al.

Basic information

Original name

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data

Authors

SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution), Marie BUDÍKOVÁ (203 Czech Republic, belonging to the institution), Jan B. VERMORKEN (56 Belgium), Ivanka HOROVÁ (203 Czech Republic, belonging to the institution), Břetislav GÁL (203 Czech Republic, belonging to the institution), Eric RAYMOND (250 France), A. de GRAMONT (250 France) and Sandrine FAIVRE (250 France)

Edition

Oral oncology, AMSTERDAM, ELSEVIER SCIENCE BV, 2017, 1368-8375

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 4.636

RIV identification code

RIV/00216224:14110/17:00099947

Organization unit

Faculty of Medicine

DOI

UT WoS

000414323200011

Keywords in English

c-MET receptor; Head and neck cancer; Immunohistochemistry; Overexpression; Prognostic factor; Predictive factor

Tags

Tags

International impact, Reviewed
Změněno: 18/3/2018 16:58, Soňa Böhmová

Abstract

V originále

Objectives: The hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) ligand/receptor axis has been implicated in pathogenesis of malignant diseases including squamous cell carcinoma of the head and neck (SCCHN). Overexpression of c-MET has been reported as a common molecular abnormality in SCCHN, although its prognostic and predictive value remains to be validated. Methods: We systematically searched literature for studies evaluating c-MET expression on immunohistochemistry in newly diagnosed, non-metastatic SCCHN. The c-MET expressing cases were classified into three categories according to predefined cut-off values for positivity. Our aim was to assess the prevalence of c-MET expression and its relationship with selected clinicopathological variables. Results: Twenty-eight studies with 2019 cases were included. Relative frequencies of c-MET expression above cut-off levels I, II, and III were 81.8%, 63.8%, and 46.2%, respectively. Differences between these three values were statistically significant (p < 1.0 x 10(-6)). Above cut-off level II, c-MET positivity was associated with worse overall survival (p = 4.0 x 10(-6)), positive nodal status (p = 1.0 x 10(-4)), higher disease stage (p = 7.0 x 10(-4)), older age (p = 2.1 x 10(-3)), disease recurrence (p = 2.0 x 10(-2)), and primary tumour localization in the oral cavity (p = 2.3 x 10(-2)). Above cut-off level III, c-MET positivity was associated with worse disease-free or progression-free survival (p = 9.0 x 10(-6)), p16 negativity ( p = 2.4 x 10(-4)), worse overall survival (p = 4.0 x 10(-4)), positive epidermal growth factor receptor (EGFR) status (p = 7.2 x 10(-4)), and larger primary tumours (p = 4.6 x 10(-3)). Conclusion: In SCCHN, immunohistochemical overexpression of c-MET above cut-off levels III and particularly II was associated with inferior survival outcomes and advanced disease. Moreover, it represents a promising predictive biomarker for c-MET targeting, yet the optimal scoring method remains to be defined.